Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02234583




Registration number
NCT02234583
Ethics application status
Date submitted
4/09/2014
Date registered
9/09/2014
Date last updated
23/07/2020

Titles & IDs
Public title
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Scientific title
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Secondary ID [1] 0 0
2013-005164-26
Secondary ID [2] 0 0
DS5565-A-E312
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pain Associated With Fibromyalgia 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - DS-5565

Experimental: DS-5565 - Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.


Treatment: Drugs: DS-5565
DS-5565 15 mg tablet for oral administration
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Average Daily Pain Score (ADPS) for DS-5565
Timepoint [1] 0 0
Day 0 (baseline) up to to Week 52 postdose
Secondary outcome [1] 0 0
Number of Participants With Much Improved or Better (=2) Status in Status at Week 52 As Assessed by the Patient-Rated Global Impression of Change
Timepoint [1] 0 0
Week 52 postdose
Secondary outcome [2] 0 0
Hospital Anxiety Depression Scale (HADS) Depression and Anxiety Scores for DS-5565
Timepoint [2] 0 0
Day 0 (baseline) up to Week 52 postdose
Secondary outcome [3] 0 0
EuroQol Five Dimensions Questionnaire (EQ-5D) Measure for DS-5565
Timepoint [3] 0 0
Day 0 (baseline) up to Week 52 postdose
Secondary outcome [4] 0 0
Short Form-36 (SF-36) Measure for DS-5565
Timepoint [4] 0 0
Day 0 (baseline) to Week 52 postdose
Secondary outcome [5] 0 0
Pain-Associated Sleep Interference as Assessed by Average Daily Sleep Interference Score (ADSIS) for DS-5565
Timepoint [5] 0 0
Day 0 (baseline) up to Week 52 postdose

Eligibility
Key inclusion criteria
- Able to give written informed consent

- Completed participation (i.e. completed the End-of-Tapering visit) in a preceding
study of DS 5565 in FM (DS5565-A-E309, DS5565-A-E310, or DS5565-A-E311)

- Women of child-bearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy during the study and for 4 weeks after study
completion

- Able to complete subject-reported questionaires per the investigator's judgement

- The subject must not have experienced any significant safety issues during the
preceding study that, in the investigator's judgment, would adversely impact the
subject's well-being in the long-term extension

De Novo Subjects

- Age = 18 years

- Able to give written informed consent

- Able to complete subject-reported questionnaires per the investigator's judgment

- At screening, subjects must meet the 1990 American College of Rheumatology (ACR)
criteria for FM, i.e. widespread pain present for at least 3 months and pain in at
least 11 of 18 specific tender point sites. In addition, the 2010 ACR criteria must be
met:

- Widespread pain index (WPI) = 7 and symptom severity (SS) scale score = 5, or WPI
3 to 6 and SS scale score = 9

- Symptoms have been present at a similar level for at least 3 months

- The subject does not have a disorder that would otherwise explain the pain

- ADPS of = 4 on the 11-point numeric rating scale (NRS) over the past 7 days prior to
first dose (based on completion of at least 4 daily pain diaries during the 7-day
baseline period)

- Subject must have documented evidence of a fundoscopic examination (with pupil
dilation) within 12 months prior to screening or at screening

- Women of child-bearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy during the study and for 4 weeks after study
completion
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Clinically significant unstable neurologic, psychiatric, ophthalmologic,
hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease
(e.g. severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction)
or any other concurrent disease during the preceding study (for rollover subjects) or
within 12 months prior to screening (for de novo subjects) that in the opinion of the
investigator would interfere with study participation or assessment of safety and
tolerability

- Subjects who are at risk of suicide as defined by their responses to the C-SSRS or in
the opinion of the investigator.

- Subjects with severe or uncontrolled depression that, in the judgment of the
investigator, makes the subject inappropriate for entry into the study

- Subjects with pain due to other conditions (e.g. DPNP or post-herpetic neuralgia)
that, in the opinion of the investigator, would confound assessment or self-evaluation
of the pain associated with FM

- Subjects with pain due to any widespread inflammatory musculoskeletal disorder (e.g.
rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM.

- Abuse or dependence of prescription medications, street drugs, or alcohol within the
last 1 year

- A diagnosis of untreated sleep apnea or initiation of treatment for sleep apnea within
the past 3 months

- Known hypersensitivity to a2d ligands or other components of the study medications

- Pregnancy or breast-feeding, or intent to become pregnant during the study period

- Abnormal investigative tests (i.e. ECGs) and laboratory values judged by the
investigator to be clinically significant at the End-of-Treatment visit (Visit - Week
13) in the preceding study (for rollover subjects) or at screening (for de novo
subjects), with particular focus on:

For De Novo Subjects Only

- Unable to undergo pre-study washout of prohibited concomitant medications (as listed
in Section 5.2.1 of the protocol)

- Current severe or uncontrolled major depressive disorder or anxiety disorders as
assessed by the Mini-international Neuropsychiatric Interview (MINI) interview
(Version 6.0) at screening are excluded, but mild to moderate major depression or
anxiety disorders are permitted provided that the investigator assesses the patient as
clinically stable and appropriate for entry into the study

- Any diagnosis of lifetime bipolar disorder or psychotic disorder

- Subject is currently enrolled in or has not yet completed at least 30 days since
ending another investigational device or drug study or is receiving other
investigational agents

- Subject is an employee of the study center, an immediate family member* of an employee
of the study center, or an employee of Daiichi Sankyo, INC Research, or any of the
study vendors supporting this study. *(spouse, parent, child, or sibling, whether
biological or legally adopted)

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/02/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/04/2017
Sample size
Target
Accrual to date
Final
2485
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- Campsie
Recruitment hospital [3] 0 0
- Coffs Harbour
Recruitment hospital [4] 0 0
- St. Leonards
Recruitment hospital [5] 0 0
- Maroochydore
Recruitment hospital [6] 0 0
- Sherwood
Recruitment hospital [7] 0 0
- Southport
Recruitment hospital [8] 0 0
- Woodville
Recruitment hospital [9] 0 0
- Hobart
Recruitment hospital [10] 0 0
- Clayton
Recruitment hospital [11] 0 0
- Malvern East
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Campsie
Recruitment postcode(s) [3] 0 0
- Coffs Harbour
Recruitment postcode(s) [4] 0 0
- St. Leonards
Recruitment postcode(s) [5] 0 0
- Maroochydore
Recruitment postcode(s) [6] 0 0
4075 - Sherwood
Recruitment postcode(s) [7] 0 0
- Sherwood
Recruitment postcode(s) [8] 0 0
- Southport
Recruitment postcode(s) [9] 0 0
- Woodville
Recruitment postcode(s) [10] 0 0
- Hobart
Recruitment postcode(s) [11] 0 0
- Clayton
Recruitment postcode(s) [12] 0 0
- Malvern East
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Montana
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
North Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Oregon
Country [27] 0 0
United States of America
State/province [27] 0 0
Pennsylvania
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
South Dakota
Country [30] 0 0
United States of America
State/province [30] 0 0
Tennessee
Country [31] 0 0
United States of America
State/province [31] 0 0
Texas
Country [32] 0 0
United States of America
State/province [32] 0 0
Utah
Country [33] 0 0
United States of America
State/province [33] 0 0
Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Washington
Country [35] 0 0
Austria
State/province [35] 0 0
Klagenfurt
Country [36] 0 0
Austria
State/province [36] 0 0
Senftenberg
Country [37] 0 0
Austria
State/province [37] 0 0
Vienna
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Burgas
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Pleven
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Plovdiv
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Ruse
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Sevlievo
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Sofia
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Targovishte
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Varna
Country [46] 0 0
Canada
State/province [46] 0 0
British Columbia
Country [47] 0 0
Canada
State/province [47] 0 0
Manitoba
Country [48] 0 0
Canada
State/province [48] 0 0
Ontario
Country [49] 0 0
Canada
State/province [49] 0 0
Quebec
Country [50] 0 0
Chile
State/province [50] 0 0
Region 11
Country [51] 0 0
Chile
State/province [51] 0 0
Region X
Country [52] 0 0
Czechia
State/province [52] 0 0
Chocen
Country [53] 0 0
Czechia
State/province [53] 0 0
Pilsen
Country [54] 0 0
Czechia
State/province [54] 0 0
Prague
Country [55] 0 0
Czechia
State/province [55] 0 0
Ricany
Country [56] 0 0
Czechia
State/province [56] 0 0
Rychnov nad Kneznou
Country [57] 0 0
Denmark
State/province [57] 0 0
Aalborg
Country [58] 0 0
Denmark
State/province [58] 0 0
Odense
Country [59] 0 0
Estonia
State/province [59] 0 0
Tallinn
Country [60] 0 0
Estonia
State/province [60] 0 0
Tartu
Country [61] 0 0
Finland
State/province [61] 0 0
Hyvinkaa
Country [62] 0 0
Finland
State/province [62] 0 0
Kuopio
Country [63] 0 0
France
State/province [63] 0 0
Cedex
Country [64] 0 0
France
State/province [64] 0 0
Nord
Country [65] 0 0
France
State/province [65] 0 0
Elancourt
Country [66] 0 0
Germany
State/province [66] 0 0
Berlin
Country [67] 0 0
Germany
State/province [67] 0 0
Bohlen
Country [68] 0 0
Germany
State/province [68] 0 0
Dresden
Country [69] 0 0
Germany
State/province [69] 0 0
Hannover
Country [70] 0 0
Germany
State/province [70] 0 0
Leipzig
Country [71] 0 0
Germany
State/province [71] 0 0
Magdeburg
Country [72] 0 0
Germany
State/province [72] 0 0
Mainz
Country [73] 0 0
Germany
State/province [73] 0 0
Stadtroda
Country [74] 0 0
Hungary
State/province [74] 0 0
Balassagyarmat
Country [75] 0 0
Hungary
State/province [75] 0 0
Budapest
Country [76] 0 0
Hungary
State/province [76] 0 0
Debrecen
Country [77] 0 0
Hungary
State/province [77] 0 0
Nyiregyhaza
Country [78] 0 0
Latvia
State/province [78] 0 0
Baldone
Country [79] 0 0
Latvia
State/province [79] 0 0
Balvi
Country [80] 0 0
Latvia
State/province [80] 0 0
Jekabpils
Country [81] 0 0
Latvia
State/province [81] 0 0
Liepaja
Country [82] 0 0
Latvia
State/province [82] 0 0
Ogre
Country [83] 0 0
Latvia
State/province [83] 0 0
Riga
Country [84] 0 0
Latvia
State/province [84] 0 0
Ventspils
Country [85] 0 0
Lithuania
State/province [85] 0 0
Kaunas
Country [86] 0 0
Lithuania
State/province [86] 0 0
Klaipeda
Country [87] 0 0
Lithuania
State/province [87] 0 0
Vilnius
Country [88] 0 0
New Zealand
State/province [88] 0 0
Auckland
Country [89] 0 0
New Zealand
State/province [89] 0 0
Hamilton
Country [90] 0 0
New Zealand
State/province [90] 0 0
Nelson
Country [91] 0 0
New Zealand
State/province [91] 0 0
Tauranga
Country [92] 0 0
New Zealand
State/province [92] 0 0
Wellington
Country [93] 0 0
Norway
State/province [93] 0 0
Alesund
Country [94] 0 0
Norway
State/province [94] 0 0
Hamar
Country [95] 0 0
Norway
State/province [95] 0 0
Hønefoss
Country [96] 0 0
Norway
State/province [96] 0 0
Klofta
Country [97] 0 0
Norway
State/province [97] 0 0
Lillehammer
Country [98] 0 0
Norway
State/province [98] 0 0
Stavanger
Country [99] 0 0
Poland
State/province [99] 0 0
Elblag
Country [100] 0 0
Poland
State/province [100] 0 0
Gdansk
Country [101] 0 0
Poland
State/province [101] 0 0
Katowice
Country [102] 0 0
Poland
State/province [102] 0 0
Kraków
Country [103] 0 0
Poland
State/province [103] 0 0
Lublin
Country [104] 0 0
Poland
State/province [104] 0 0
Nadarzyn
Country [105] 0 0
Poland
State/province [105] 0 0
Nowa Sol
Country [106] 0 0
Poland
State/province [106] 0 0
Torun
Country [107] 0 0
Poland
State/province [107] 0 0
Tychy
Country [108] 0 0
Poland
State/province [108] 0 0
Warsaw
Country [109] 0 0
Poland
State/province [109] 0 0
Wroclaw
Country [110] 0 0
Portugal
State/province [110] 0 0
Aveiro
Country [111] 0 0
Portugal
State/province [111] 0 0
Guimaraes
Country [112] 0 0
Portugal
State/province [112] 0 0
Porto
Country [113] 0 0
Portugal
State/province [113] 0 0
Vila Nova de Gaia
Country [114] 0 0
Puerto Rico
State/province [114] 0 0
Ponce
Country [115] 0 0
Puerto Rico
State/province [115] 0 0
San Juan
Country [116] 0 0
Romania
State/province [116] 0 0
Bacau
Country [117] 0 0
Romania
State/province [117] 0 0
Bucharest
Country [118] 0 0
Romania
State/province [118] 0 0
Targu Mures
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Krasnoyarsk
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Moscow
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Nizhniy Novgarad
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Stavropol
Country [123] 0 0
Serbia
State/province [123] 0 0
Belgrade
Country [124] 0 0
Slovakia
State/province [124] 0 0
Banska Bystrica
Country [125] 0 0
Slovakia
State/province [125] 0 0
Bratislava
Country [126] 0 0
Slovakia
State/province [126] 0 0
Dubnica nad Vahom
Country [127] 0 0
Slovakia
State/province [127] 0 0
Galanta
Country [128] 0 0
Slovakia
State/province [128] 0 0
Krompachy
Country [129] 0 0
Slovakia
State/province [129] 0 0
Pieštany
Country [130] 0 0
Slovakia
State/province [130] 0 0
Presov
Country [131] 0 0
Slovenia
State/province [131] 0 0
Ljubljana
Country [132] 0 0
Slovenia
State/province [132] 0 0
Slovenj Gradec
Country [133] 0 0
South Africa
State/province [133] 0 0
Chatsworth
Country [134] 0 0
South Africa
State/province [134] 0 0
Gautang
Country [135] 0 0
South Africa
State/province [135] 0 0
Kwazulu Natal
Country [136] 0 0
South Africa
State/province [136] 0 0
Western Cape
Country [137] 0 0
South Africa
State/province [137] 0 0
Stellenbosch
Country [138] 0 0
Spain
State/province [138] 0 0
A Coruna
Country [139] 0 0
Spain
State/province [139] 0 0
Barcelona
Country [140] 0 0
Spain
State/province [140] 0 0
Granada
Country [141] 0 0
Spain
State/province [141] 0 0
Madrid
Country [142] 0 0
Ukraine
State/province [142] 0 0
Dnipropetrovsk
Country [143] 0 0
Ukraine
State/province [143] 0 0
Ivano-Frankivsk
Country [144] 0 0
Ukraine
State/province [144] 0 0
Kharkiv
Country [145] 0 0
Ukraine
State/province [145] 0 0
Kherson
Country [146] 0 0
Ukraine
State/province [146] 0 0
Kyiv
Country [147] 0 0
Ukraine
State/province [147] 0 0
Lviv
Country [148] 0 0
Ukraine
State/province [148] 0 0
Vinnytsia
Country [149] 0 0
Ukraine
State/province [149] 0 0
Zaporizhzhia
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Cornwall
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Derbyshire
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Essex
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Greater Manchester
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Lancashire
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Leeds
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Manchester
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Merseyside
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Northamptonshire
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Northern Ireland
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Staffordshire
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Tyne And Wear
Country [162] 0 0
United Kingdom
State/province [162] 0 0
Warwickshire
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Torpoint

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Daiichi Sankyo
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an open-label study of DS-5565 in subjects who either completed participation in a
preceding Phase 3 study of DS-5565 in fibromyalgia (FM); i.e. DS5565-A-E309 (NCT02146430),
DS5565-A-E310 (NCT02187471), or DS5565-A-E311 (NCT02187159) or are de novo subjects. Eligible
subjects will be assigned to receive open-label DS-5565 for 52 weeks. All subjects will
receive DS-5565 15 mg once daily (QD) for the first three weeks of the treatment period.
After three weeks, subjects may be titrated to 15 mg twice daily (BID) based on
protocol-specified criteria.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02234583
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Leader
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02234583